Casdin Capital PRME Position
Active8-Fund ConvergenceCasdin Capital held their position in Prime Medicine, Inc. (PRME) in Q4 2025, holding $11.0M worth of shares across 3,167,175 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
PRME is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for PM359 in 1386 days (Jan 31, 2030), making the timing of Casdin's position particularly relevant.
Short interest stands at 19.7% of float with 9.1 days to cover, indicating significant bearish positioning against Casdin's long thesis.
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
19.7%
9.1 days to cover
Casdin Capital PRME Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 3,167,175 | — | $11.0M |
| Q3 2025 | Increased | 3,167,175 | +1,600,000 | $17.5M |
| Q2 2025 | Increased | 1,567,175 | +1,200,000 | $3.9M |
| Q1 2025 | Held | 367,175 | — | $731K |
| Q4 2024 | Held | 367,175 | — | $1.1M |
| Q3 2024 | Held | 367,175 | — | $1.4M |
| Q2 2024 | Held | 367,175 | — | $1.9M |
| Q1 2024 | Held | 367,175 | — | $2.6M |
| Q4 2023 | Held | 367,175 | — | $3.3M |
| Q3 2023 | Held | 367,175 | — | $3.5M |
| Q2 2023 | Decreased | 367,175 | -367,175 | $5.4M |
| Q1 2023 | New | 734,350 | +734,350 | $9.0M |
Frequently Asked Questions
Does Casdin Capital own PRME?
Yes. As of Q4 2025, Casdin Capital holds 3,167,175 shares of Prime Medicine, Inc. (PRME) valued at $11.0M. This data comes from their SEC 13F filing.
How many hedge funds own PRME?
8 specialist biotech hedge funds currently hold PRME, including Redmile Group, RA Capital Management, Baker Bros. Advisors and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy PRME?
Casdin Capital's position in PRME was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's PRME position increasing or decreasing?
Casdin Capital held their PRME position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PRMECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →